Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-EN Version v3-FR
Language English French
Date Updated 2022-03-11 2020-09-16
Drug Identification Number 00897639 00897639
Brand name ISOPROTERENOL HYDROCHLORIDE INJECTION USP ISOPROTERENOL HYDROCHLORIDE INJECTION USP
Common or Proper name ISOPROTERENOL HYDROCHLORIDE INJECTION USP ISOPROTERENOL HYDROCHLORIDE INJECTION USP
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients ISOPROTERENOL HYDROCHLORIDE ISOPROTERENOL HYDROCHLORIDE
Strength(s) 0.2MG 0.2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 10 X 1mLa 10 X 1mLa
ATC code C01CA C01CA
ATC description CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date 2020-12-25
Actual start date 2020-11-26
Estimated end date Unknown 2021-06-25
Actual end date 2022-03-10
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments